(Q33540949)

27 July 2017

1 reference

title

Selective estrogen receptor modulators: Women's panacea for the next millennium? (English)

1 reference

27 July 2017

C P Spencer

1

1 reference

27 July 2017

E P Morris

series ordinal

2

1 reference

27 July 2017

J M Rymer

series ordinal

3

1 reference

27 July 2017

language of work or name

English

0 references

publication date

1 March 1999

1 reference

American Journal of Obstetrics and Gynecology

27 July 2017

published in

1 reference

27 July 2017

volume

180

1 reference

27 July 2017

issue

3 Pt 1

1 reference

27 July 2017

page(s)

763-770

1 reference

Prevalence of high blood cholesterol among US adults. An update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel.

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

The Framingham Disability Study: relationship of various coronary heart disease manifestations to disability in older persons living in the community

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Breast cancer trends. Incidence, mortality, and survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Changing incidence and residual lifetime risk of common osteoporosis-related fractures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Perspective. How many women have osteoporosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Long-term estrogen replacement therapy prevents bone loss and fractures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Hormone therapy to prevent disease and prolong life in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Postmenopausal Estrogen and Progestin Use and the Risk of Cardiovascular Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Postmenopausal hormone therapy and mortality.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

A new derivative of triphenylethylene: effect on implantation and mode of action in rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Role of Estrogens in Ovulation: A Study Using the Estrogen-Antagonist, I.C.I. 46,474

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Effect of some triphenylethylenes on oestradiol binding in vitro to macromolecules from uterus and anterior pituitary.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Tamoxifen as an anti-tumour agent: oestrogen binding as a predictive test for tumour response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone-deficient rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Effects of tamoxifen on spinal bone density in women with breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Long-term adjuvant tamoxifen in early breast cancer: effect on bone mineral density in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Oestrogen and bone density

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Apparent beneficial effects of tamoxifen on bone mineral content in patients with breast cancer: Preliminary study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Effect of long term tamoxifen treatment on bone turnover in women with breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Bone mineral content of women receiving tamoxifen for mastalgia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Antiestrogen and antiandrogen administration reduce bone mass in the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Does long-term administration of tamoxifen affect bone mineral density?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Risk of endometrial cancer after tamoxifen treatment of breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

What do we know and what don't we know about tamoxifen in the human uterus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Pathology of endometrium treated with tamoxifen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Tamoxifen and toremifene lower serum cholesterol by inhibition of delta 8-cholesterol conversion to lathosterol in women with breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Effects of tamoxifen on cardiovascular risk factors in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Tamoxifen inhibits arterial accumulation of LDL degradation products and progression of coronary artery atherosclerosis in monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

7 January 2021

Tamoxifen and thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Effect of tamoxifen on oestrogen binding, lipid and lipoprotein concentrations and blood clotting parameters in premenopausal women with breast pain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Mechanisms of action of antiestrogens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Cloning of a novel receptor expressed in rat prostate and ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Non-steroidal antioestrogens--receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Antagonism of estrogen action with a new benzothiophene derived antiestrogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

The effects of raloxifene on tibia histomorphometry in ovariectomized rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Raloxifene preserves bone strength and bone mass in ovariectomized rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCL)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Dual-energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Estrogen and raloxifene stimulate transforming growth factor-beta 3 gene expression in rat bone: a potential mechanism for estrogen- or raloxifene-mediated bone maintenance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Preclinical data for Droloxifene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Pharmacologic and biologic properties of droloxifene, a new antiestrogen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Pharmacokinetics of droloxifene and its metabolites in breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Droloxifene, a new anti-oestrogen in postmenopausal advanced breast cancer: preliminary results of a double-blind dose-finding phase II trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Droloxifene, a new antiestrogen: its role in metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Droloxifene prevents ovariectomy-induced bone loss in tibiae and femora of aged female rats: a dual-energy X-ray absorptiometric and histomorphometric study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Common mechanism for the estrogen agonist and antagonist activities of droloxifene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Induction of Transforming Growth Factor β by the Antiestrogens Droloxifene, Tamoxifen, and Toremifene in MCF-7 Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Centchroman: a new non-steroidal oral contraceptive in human milk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

The bone-specific estrogen centchroman inhibits osteoclastic bone resorption in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Centchroman--a non-steroidal anti-cancer agent for advanced breast cancer: phase-II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Comparison between the Effects of Tamoxifen and Toremifene on the Uterus in Postmenopausal Breast Cancer Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Antitumor effect of triphenylethylene derivative (TAT-59) against human breast carcinoma xenografts in nude mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Antiuterotrophic effects of the pure antioestrogen ICI 182,780 in adult female monkeys (Macaca nemestrina): quantitative magnetic resonance imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

17 beta-estradiol increases calcium content in fetal mouse parietal bones cultured in serum-free medium only at physiological concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

The estrogen antagonist ICI 182,780 reduces cancellous bone volume in female rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Action of "pure" antiestrogens in inhibiting estrogen receptor action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

The effect of anti-oestrogens on cell growth and progesterone receptor concentration in human endometrial cancer cells (Ishikawa).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

10.1016/S0002-9378(99)70285-1

7 January 2021

Identifiers

DOI

1 reference

27 July 2017

1 reference